Skip to main content
Pharmanutra logo

Pharmanutra — Investor Relations & Filings

Ticker · PHN ISIN · IT0005274094 LEI · 815600F8217BC7733697 XMIL Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2025-03-06 AGM Information
Country IT Italy
Listing XMIL PHN

About Pharmanutra

http://www.pharmanutra.it

PharmaNutra is a company operating in the pharmaceutical and nutraceutical sectors, focused on the development and distribution of nutritional supplements and medical devices. Grounded in scientific research, the company creates innovative solutions for health and wellness. Its core activities center on addressing nutritional deficiencies, particularly iron, through proprietary functional ingredients and technologies. The product portfolio also extends to supporting muscle and joint health, sports nutrition, and applications across various therapeutic areas, including gynecology, orthopedics, hematology, and gastroenterology. The company emphasizes the development of effective and safe products supported by clinical evidence.

Recent filings

Filing Released Lang Actions
Relazione Illustrativa sulla nomina Collegio Sindacale 2025
AGM Information Classification · 1% confidence The document is titled "RELAZIONE ILLUSTRATIVA DEL CONSIGLIO DI AMMINISTRAZIONE SULLE MATERIE ALL'ORDINE DEL GIORNO DELL'ASSEMBLEA ORDINARIA DI PHARMANUTRA S.P.A. CONVOCATA PER IL GIORNO 16 APRILE 2025" (Explanatory Report of the Board of Directors on the items on the agenda of the Ordinary General Meeting of PHARMANUTRA S.P.A. convened for April 16, 2025). The content specifically details the procedures for the nomination of the Board of Statutory Auditors ('Collegio Sindacale') which is a key item typically addressed at an Annual General Meeting (AGM). While it is an explanatory report related to an AGM agenda item, the core subject matter—the election/nomination process for a statutory body—is highly relevant to shareholder meetings and governance. However, the document itself is a detailed report/presentation to shareholders regarding the agenda items, not the final voting results (DVA) or the general proxy solicitation materials (PSI). Given the context of an explanatory report accompanying the agenda for an AGM, and the focus on board/governance structure (appointment of auditors), it aligns closely with materials presented *at* or *for* the AGM. Since the primary focus is the explanatory report for the AGM agenda, and it is not a standard 10-K, ER, or IR, the most fitting category is AGM-R (AGM Information), as it is the explanatory document for the meeting.
2025-03-06 Italian
NOTICE CALLING THE ORDINARY AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS_16 APRIL 2025
AGM Information Classification · 1% confidence The document is explicitly titled 'NOTICE CALLING THE ORDINARY & EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF PHARMANUTRA S.P.A.' and details the agenda, date (16 April 2025), location, and procedures for shareholder participation, voting, and proxy granting for this meeting. This content directly corresponds to the definition of materials shared during an Annual General Meeting (AGM). Although it mentions approval of financial statements (1.1) and remuneration reports (2.1), the primary purpose of this specific document is the formal convocation and procedural setup for the meeting itself, making AGM-R the most accurate classification over 10-K or DEF 14A.
2025-03-06 English
AVVISO DI CONVOCAZIONE DI ASSEMBLEA ORDINARIA E STRAORDINARIA_16 aprile 2025
AGM Information Classification · 1% confidence The document is titled "AVVISO DI CONVOCAZIONE DI ASSEMBLEA ORDINARIA E STRAORDINARIA DI PHARMANUTRA S.P.A." (Notice of Call for Ordinary and Extraordinary Shareholders' Meeting of Pharmanutra S.p.A.). It details the date, time, location (virtual attendance only), and the specific items on the agenda (Ordine del Giorno) for both the ordinary and extraordinary parts of the meeting. The agenda includes approval of the 2024 financial statements, remuneration policy, appointment of the Board of Statutory Auditors, authorization for share buybacks, and amendments to the bylaws. It also outlines procedures for shareholder participation, voting via a designated representative (Rappresentante Designato), requesting agenda additions, and submitting questions. This content is characteristic of a formal notice sent to shareholders to convene a general meeting, which aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI) or, more broadly, materials related to the Annual General Meeting (AGM-R). Since it is the formal notice calling the meeting and detailing voting procedures and agenda items, AGM-R is the most appropriate primary classification, as it directly relates to the Annual General Meeting process, even though it contains elements that might overlap with DEF 14A (remuneration) or DVA (voting results, which happen later). Given the explicit mention of the meeting call and agenda, AGM-R is selected.
2025-03-06 Italian
CDA DELIBERA DI CONVOCARE L’ASSEMBLEA ORDINARIA E STRAORDINARIA DELLA SOCIETÀ_BOARD OF DIRECTORS CONVENE THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING
AGM Information Classification · 1% confidence The document is an official regulatory announcement (indicated by 'Informazione Regolamentata' and the structure) stating that the Board of Directors ('CDA' / 'Board of Directors') has resolved to convene an Ordinary and Extraordinary Shareholders' Meeting ('ASSEMBLEA ORDINARIA E STRAORDINARIA'). The agenda for this meeting includes the approval of the 2024 financial statements, remuneration policy review, appointment of auditors, authorization for treasury share transactions, and sustainability reporting certification, which are typical items for an Annual General Meeting (AGM). Although the document announces the meeting, it is not the proxy statement (DEF 14A/PSI) itself, nor is it the full AGM presentation (AGM-R). It is the formal notice/resolution to call the meeting. Since the primary purpose is announcing the convening of the shareholders' meeting, and the agenda covers standard AGM items, the most appropriate classification is related to the AGM process. Given the options, this announcement is a precursor to the AGM. However, the content is a formal resolution to call the meeting, which often falls under general regulatory announcements or specific meeting notices. Since the agenda explicitly covers items typically voted on at the AGM, and the document is a formal notice of the meeting, it is closely related to AGM proceedings. If a specific 'Notice of Meeting' code existed, it would be preferred. Given the choices, and recognizing that the core subject is the convening of the meeting where key governance and financial approvals happen, it relates strongly to the AGM process. Since the document is a formal announcement of the meeting, and not the proxy materials or the meeting presentation itself, it is best classified as a general regulatory announcement (RNS) or potentially related to the AGM process. Looking closely at the agenda items (approving financial statements, remuneration policy, appointing auditors), these are standard AGM items. If the document were the proxy materials, it would be PSI. If it were the presentation, it would be AGM-R. As it is the resolution to call the meeting, RNS is a safe fallback, but since the subject is explicitly the Shareholders' Meeting, and the items are governance/financial approvals, it is a strong candidate for a document related to the AGM process. Given the options, and the fact that it is a formal regulatory filing announcing a future AGM, RNS (Regulatory Filings) is the most accurate general category for this type of notice when a specific 'Notice of Meeting' code is absent, although it is highly relevant to AGM-R. I will select RNS as the most fitting general regulatory announcement type for a notice of meeting resolution, as it is not the AGM material itself, nor the proxy statement.
2025-03-04 Italian
Pharmanutra: Preliminary revenues 2024
Earnings Release Classification · 1% confidence The document is a press release titled 'Pharmanutra: Preliminary revenues 2024' issued on January 13, 2025. It explicitly states that the Board of Directors approved the 'preliminary sales figures for the financial year 2024 (unaudited)'. It provides key financial highlights (consolidated revenues, growth rates by geography and product line) but notes that the complete annual figures will be approved later (March 14, 2025). This structure—an early, unaudited release of key financial performance metrics for a period—is characteristic of an Earnings Release (ER). It is not the full Annual Report (10-K) or the comprehensive Interim Report (IR), as it focuses only on preliminary revenue highlights. FY 2024
2025-01-13 English
Pharmanutra: Ricavi preliminari 2024
Earnings Release Classification · 1% confidence The document is a press release dated January 13, 2025, titled "Pharmanutra: Ricavi preliminari 2024" (Pharmanutra: Preliminary 2024 Revenues). It explicitly states that the Board of Directors approved the preliminary sales data for the 2024 fiscal year, which are not yet audited. It provides key financial highlights, including consolidated revenue growth (+15%) and detailed breakdowns by market and product line. Crucially, it mentions that the full annual data will be approved by the Board on March 14, 2025. This structure—announcing preliminary results before the final audited report—is characteristic of an Earnings Release (ER), which provides the initial announcement of periodical financial results (in this case, preliminary annual results). It is not the comprehensive Annual Report (10-K) or the subsequent formal Audit Report (AR). FY 2024
2025-01-13 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.